TrueBinding Stock

HealthTech

TrueBinding has developed a proprietary drug discovery platform aimed at generating novel monoclonal antibody therapeutics for complex and underserved conditions. The company's advanced antibody development platform targets diseases like Alzheimer's, Parkinson's, and Autism Spectrum Disorder. This enables patients with neurodegenerative and neurodevelopmental disorders to access innovative treatments that address neuroinflammation and protein aggregation.